• Home
  • Study Details

Randomized, double-blind, phase III clinical trial of neoadjuvant chemotherapy or a placebo in patients with triple-negative breast cancer followed by adjubant chemotherapy or a placebo

To determine if the usual chemotherapy given before surgery for breast cancer plus an experimental drug is better than the usual chemotherapy plus a placebo.

Age & Gender

  • 18 years ~ 99 years
  • Male, Female


North Carolina (Edgecombe, Nash)

What will be asked of you

Screening, Clinic visits , Imaging

In-person visits : 50 +
Total length of participation : 9 years

Looking for Specific Volunteers

Able to participate:

  • Diagnosed with invasive adenocarcinoma of the breast

Not eligible if:

  • Definitive clinical or radiologic evidence of metastatic disease
  • Previous history of contralateral or ipsilateral invasive breast cancer
  • History of non-breast malignancies
  • Cardiac disease that would prevent the use of the study drugs

Contact the Team

Visit Location

100% Remote (online, phone, text)

Additional Study Information

Principal Investigator

Jayadev Manikkam umakanthan
UNC Hospitals - Nash

Study Topics

Cancer (Breast)
Surgery and post-operative healing
Women's Health
Men's Health

IRB Number


logo for the North Carolina Translational and Clinical Sciences Institute
logo for UNC Health
logo for UNC School of Medicine
logo for UNC Research
Research for Me logo

Copyright © 2013-2020 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH.  This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.


  • This email address is being protected from spambots. You need JavaScript enabled to view it.